MedTrace Logo

Maintenance Therapy Using Lenalidomide in Myeloma

NCT00430365 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2026-04-06

No results posted yet for this study

Summary

Maintenance treatment of myeloma.

Conditions

Interventions

DRUG

lenalidomide

oral drug

DRUG

placebo

oral placebo

Sponsors & Collaborators

  • Intergroupe Francophone du Myelome

    collaborator NETWORK

  • Celgene

    collaborator INDUSTRY

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • ATTAL Michel, Pr · University Hospital, Toulouse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2017-09-30
Completion
2018-09-30

Countries

  • Belgium
  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430365 on ClinicalTrials.gov